RLAY

Relay Therapeutics Inc

18.60

Nov 06 • 3:59 PM ET +1.60 (9.41%)

18.51

Aftermarket • 5:51 PM ET -0.09 (-0.48%)

Healthcare Biotechnology USA Mid NASD

Nov 06, 7:32 PMModerna earnings beat drives biotech rebound, lifting Relay Therapeutics 9% in Friday trading

Peers: CELC OLMA ARVN PVLA ERAS IDYA TNGX LLY NVS AZN

| Held by: VTI XBI IWM VXF IWO IBB DFAS TCAF VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	4.11B
Enterprise Value	3.29B
Income	-293.63M
Sales	10.35M
Book/sh	3.73
Cash/sh	3.84
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	192
IPO	Jul 16, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	397.09
P/B	4.99
P/C	4.84
P/FCF	-
EV/EBITDA	-
EV/Sales	317.70
Quick Ratio	14.62
Current Ratio	14.62
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.51
EPS next Y	-1.59
EPS next Q	-0.36
EPS this Y	3.06%
EPS next Y	-2.10%
EPS next 5Y	0.51%
EPS past 3/5Y	14.61% 8.85%
Sales past 3/5Y	123.20% -28.58%
EPS Y/Y TTM	13.76%
Sales Y/Y TTM	23.86%
EPS Q/Q	13.28%
Sales Q/Q	-
Earnings	Nov 04 AMC
EPS/Sales Surpr.	6.75% 4.12%

Insider Own	21.67%
Insider Trans	-12.18%
Inst Own	99.86%
Inst Trans	18.05%
ROA	-37.37%
ROE	-41.16%
ROIC	-34.85%
Gross Margin	83.16%
Oper. Margin	-3094.58%
Profit Margin	-2837.03%
SMA20	3.54%
SMA50	1.57%
SMA200	21.96%
Trades

Shs Outstand	219.50M
Shs Float	173.08M
Short Float	25.44%
Short Ratio	15.41
Short Interest	44.03M
52W High	21.27 -12.55%
52W Low	5.95 212.61%
Volatility	8.34% 6.15%
ATR (14)	1.13
RSI (14)	52.70
Beta	1.74
Rel Volume	1.12
Avg Volume	2.86M
Volume	3,199,765

Perf Week	1.36%
Perf Month	6.84%
Perf Quarter	-6.72%
Perf Half Y	45.77%
Perf YTD	119.86%
Perf Year	184.84%
Perf 3Y	128.78%
Perf 5Y	-47.64%
Perf 10Y	-
Recom	1.08
Target Price	28.25
Prev Close	17.00
Price	18.60
Change %	9.41%

Consensus

Strong Buy

Avg. Price Target

$28.25

Implied Upside

+51.9%

Analysts13incl. previous ratings

Rating Distribution13 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 16, 2026	Initiated	CCanaccord Genuity	Buy	$29	+55.9%
Jul 08, 2026	Initiated	JJP Morgan	Overweight	$28	+50.5%
Jan 26, 2026	Upgrade	OOppenheimer	Perform → Outperform	$14	-24.7%
Dec 12, 2025	Upgrade	WWells Fargo	Equal Weight → Overweight	$13	-30.1%
Sep 04, 2025	Resumed	GGuggenheim	Buy	$15	-19.4%
Apr 17, 2025	Initiated	WWells Fargo	Equal Weight	$4	-78.5%
Sep 10, 2024	Upgrade	JJefferies	Hold → Buy	$10.60 → $16	-14.0%
Sep 10, 2024	Resumed	GGoldman	Buy	$20	+7.5%
Sep 10, 2024	Downgrade	OOppenheimer	Outperform → Perform
May 10, 2024	Upgrade	BBarclays	Equal Weight → Overweight	$15	-19.4%
Apr 20, 2023	Upgrade	JJefferies	Underperform → Hold	$12.50	-32.8%
Apr 19, 2023	Upgrade	RRaymond James	Outperform → Strong Buy	$29	+55.9%
Apr 13, 2023	Initiated	RRaymond James	Outperform	$29	+55.9%
Feb 03, 2023	Initiated	OOppenheimer	Outperform	$33	+77.4%
Sep 30, 2022	Initiated	BBarclays	Equal Weight	$23	+23.7%
Sep 02, 2022	Initiated	SStifel	Buy	$40	+115.1%
Jun 06, 2022	Initiated	JJefferies	Underperform	$13	-30.1%
Feb 01, 2022	Initiated	BBerenberg	Buy	$45	+141.9%
Jul 21, 2021	Initiated	BBofA Securities	Buy	$50	+168.8%
Dec 15, 2020	Reiterated	HH.C. Wainwright	Buy	$54 → $57	+206.5%

Nov-04-26 04:05PM	Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire) -5.71%
Nov-02-26 04:05PM	Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November (GlobeNewswire) -5.83%
Oct-28-26 09:50PM	Relay Therapeutics Heads Into Q3 With A Rerated Stock And Burn Discipline In Focus (Earnings Whispers)
04:12PM	Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 (GlobeNewswire)
Oct-08-26 07:58PM	What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis)
04:26PM	Loading…
Oct-01-26 04:26PM	Raymond James Updates Healthcare Top Picks for October (Investing.com)
Sep-25-26 08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
Sep-01-26 04:46PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-20-26 08:03AM	This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion (Investor's Business Daily) -5.01%
Aug-06-26 04:05PM	Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
Jul-30-26 04:05PM	Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 (GlobeNewswire) +5.88%
Jul-23-26 09:05AM	An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
May-27-26 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
May-20-26 08:21PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.87%
May-19-26 04:03PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:31AM	Loading…
09:31AM	Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) (InvestorsHub)
06:02AM	This Biotech's Drug Just Wiped The Floor With Forecasts (Investor's Business Daily)
06:00AM	Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies (GlobeNewswire)
04:05AM	Relay drug shows early promise against rare blood vessel diseases (BioPharma Dive)
May-05-26 04:05PM	Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
Apr-29-26 04:05PM	Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 (GlobeNewswire)
Apr-27-26 06:00AM	Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer (GlobeNewswire)
Apr-02-26 04:05PM	Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 (GlobeNewswire) +16.43%
Mar-16-26 07:00AM	Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 (GlobeNewswire)
Feb-26-26 06:00PM	Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +12.01%
04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones (GlobeNewswire)
Feb-23-26 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March (GlobeNewswire)
Feb-19-26 05:55PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 (GlobeNewswire)
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire)
Feb-04-26 04:05PM	Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
06:27AM	Loading…
06:27AM	Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer (Pharmaceutical Business Review)
Feb-03-26 07:00AM	Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer (GlobeNewswire) +6.38%
Feb-02-26 09:51AM	Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors (Insider Monkey) +6.40%
Dec-12-25 07:00AM	Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 (GlobeNewswire)
Nov-11-25 10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)
09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks)
Nov-06-25 04:05PM	Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) -7.35%
Nov-03-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November (GlobeNewswire)
Oct-30-25 04:05PM	Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 (GlobeNewswire)
09:55AM	Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet (Zacks)
Oct-28-25 12:00PM	Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy (Zacks)
11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-14-25 09:55AM	Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade (Zacks)
Sep-21-25 09:25AM	Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 (Insider Monkey)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
12:30AM	Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY) (Insider Monkey)
Sep-05-25 06:42PM	Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week (Motley Fool)
Aug-28-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-25 11:56PM	Leerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PT (Insider Monkey)
Aug-17-25 11:41PM	Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts (Insider Monkey)
Aug-12-25 12:00PM	Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-07-25 06:35PM	Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.74%
04:05PM	Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-04-25 10:01AM	Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT (Insider Monkey) +8.63%
Jul-31-25 04:05PM	Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 (GlobeNewswire)
Jul-29-25 09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
Jul-25-25 11:33AM	RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
Jun-24-25 03:51PM	BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT (Insider Monkey)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -5.06%
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire)
Jun-09-25 11:37AM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
Jun-02-25 07:00AM	Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 (GlobeNewswire) +6.00%
May-29-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
May-27-25 09:45AM	Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders (PR Newswire)
May-23-25 12:00PM	What Makes Relay Therapeutics (RLAY) a New Buy Stock (Zacks)
May-13-25 08:49AM	Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey) -9.00%
May-08-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-07-25 06:58PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey) -6.35%
May-05-25 04:05PM	Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) -5.12%
Apr-28-25 04:05PM	Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 (GlobeNewswire)
Apr-20-25 06:19AM	Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts (Insider Monkey)
Apr-16-25 10:03AM	Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -5.43%
09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-12-25 09:28AM	Relay Therapeutics: Trying To Find That Right Price (Seeking Alpha)
Apr-09-25 09:44AM	Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple (Insider Monkey) +15.00%
05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire)
Mar-31-25 09:56AM	Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! (Insider Monkey)
Mar-05-25 09:35AM	Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) (Zacks) +6.27%
Feb-26-25 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) -13.33%
Feb-25-25 10:48AM	What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings (GuruFocus.com) -5.15%
Feb-24-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 (GlobeNewswire) +6.12%
Jan-24-25 12:09PM	Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays $17 Price Target (Insider Monkey)
Jan-07-25 04:05PM	Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:57PM	Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey)
Dec-20-24 12:00PM	Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-13-24 05:49PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
Dec-11-24 06:00AM	Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival (GlobeNewswire) +12.42%
Dec-09-24 04:05PM	Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-06-24 09:35AM	After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) (Zacks) +7.71%
Dec-05-24 06:51AM	Relay Therapeutics price target lowered to $18 from $19 at Leerink (TipRanks)
Dec-04-24 04:36PM	Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Dec-03-24 08:01AM	Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire) -6.00%
08:00AM	Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire)
Nov-20-24 09:35AM	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-19-24 09:35AM	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rahmer Peter	See remarks	Oct 28 '26	Sale	18.62	753	14,021	222,904	Oct 30 04:18 PM
Bergstrom Donald A	President, R&D	Oct 28 '26	Sale	18.62	2,252	41,932	396,878	Oct 30 04:15 PM
Catinazzo Thomas	Chief Financial Officer	Oct 28 '26	Sale	18.62	1,469	27,353	103,665	Oct 30 04:14 PM
Patel Sanjiv	President and CEO	Oct 07 '26	Sale	18.10	48,199	872,402	471,301	Oct 08 05:29 PM
Catinazzo Thomas	Chief Financial Officer	Oct 06 '26	Sale	18.59	17,717	329,322	105,134	Oct 08 05:29 PM
SANJIV PATEL	Director	Oct 07 '26	Proposed Sale	18.74	96,401	1,806,555		Oct 07 04:35 PM
THOMAS CATINAZZO	Officer	Oct 06 '26	Proposed Sale	19.39	93,153	1,806,237		Oct 06 04:21 PM
Bergstrom Donald A	President, R&D	Sep 08 '26	Sale	18.97	8,530	161,814	399,130	Sep 09 04:17 PM
Catinazzo Thomas	Chief Financial Officer	Sep 08 '26	Sale	18.94	17,717	335,560	122,851	Sep 09 04:15 PM
Patel Sanjiv	President and CEO	Sep 08 '26	Sale	18.94	48,199	912,889	519,500	Sep 09 04:12 PM
Rahmer Peter	See remarks	Aug 26 '26	Sale	20.03	4,508	90,295	223,657	Aug 28 04:43 PM
SVF Pauling (Cayman) Ltd	10% Owner	Aug 25 '26	Sale	19.40	6,000,000	116,400,000	21,904,963	Aug 28 09:01 AM
PETER RAHMER	Officer	Aug 26 '26	Proposed Sale	20.57	50,000	1,028,500		Aug 26 04:15 PM
SVF Pauling (Cayman) Ltd	Stockholder	Aug 25 '26	Proposed Sale	20.57	6,000,000	123,420,000		Aug 25 07:43 PM
Patel Sanjiv	President and CEO	Aug 17 '26	Sale	20.33	48,199	979,886	567,699	Aug 18 04:17 PM
Catinazzo Thomas	Chief Financial Officer	Aug 14 '26	Sale	19.74	17,717	349,734	140,568	Aug 18 04:16 PM
SEKAR KATHIRESAN	Director	Aug 04 '26	Proposed Sale	19.57	42,225	826,466		Aug 04 04:11 PM
SEKAR KATHIRESAN	Director	Jul 31 '26	Proposed Sale	18.79	30,000	563,553		Jul 31 04:05 PM
Catinazzo Thomas	Chief Financial Officer	Jul 28 '26	Sale	18.61	1,459	27,152	158,285	Jul 30 04:13 PM
Rahmer Peter	See remarks	Jul 28 '26	Sale	18.61	748	13,920	228,165	Jul 30 04:13 PM
Bergstrom Donald A	President, R&D	Jul 28 '26	Sale	18.61	2,237	41,631	407,660	Jul 30 04:12 PM
SEKAR KATHIRESAN	Director	Jul 21 '26	Proposed Sale	19.81	30,000	594,414		Jul 21 04:10 PM
SEKAR KATHIRESAN	Director	Jul 20 '26	Proposed Sale	19.58	66,055	1,293,555		Jul 20 04:05 PM
Bergstrom Donald A	President, R&D	Jul 06 '26	Sale	18.71	8,660	162,029	409,897	Jul 08 05:11 PM
Patel Sanjiv	President and CEO	Jul 07 '26	Sale	19.58	48,199	943,736	615,898	Jul 08 05:08 PM
Catinazzo Thomas	Chief Financial Officer	Jul 06 '26	Sale	18.69	17,717	331,131	159,744	Jul 08 05:07 PM
SANJIV PATEL	Director	Jul 07 '26	Proposed Sale	18.90	144,597	2,732,883		Jul 07 04:36 PM
Rahmer Peter	See remarks	Jun 30 '26	Sale	19.09	50,000	954,500	225,857	Jul 02 04:12 PM
PETER RAHMER	Officer	Jun 30 '26	Proposed Sale	19.74	50,000	987,000		Jun 30 04:35 PM
Catinazzo Thomas	Chief Financial Officer	Jun 22 '26	Option Exercise	4.93	169,446	834,669	239,024	Jun 24 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Jun 22 '26	Sale	16.97	187,163	3,176,865	177,461	Jun 24 04:09 PM
Bergstrom Donald A	President, R&D	Jun 22 '26	Option Exercise	4.12	93,456	385,039	512,013	Jun 24 04:09 PM
Bergstrom Donald A	President, R&D	Jun 22 '26	Sale	16.94	93,456	1,583,145	418,557	Jun 24 04:09 PM
DONALD BERGSTROM	Officer	Jun 22 '26	Proposed Sale	15.88	110,646	1,757,058		Jun 22 04:57 PM
THOMAS CATINAZZO	Officer	Jun 22 '26	Proposed Sale	15.88	204,880	3,253,494		Jun 22 04:57 PM
Catinazzo Thomas	Chief Financial Officer	May 14 '26	Sale	12.86	17,717	227,841	195,178	May 14 06:44 PM
THOMAS CATINAZZO	Officer	May 14 '26	Proposed Sale	13.22	37,234	492,233		May 14 04:24 PM
Catinazzo Thomas	Chief Financial Officer	Apr 28 '26	Sale	14.79	972	14,376	212,895	Apr 30 04:22 PM
Rahmer Peter	See remarks	Apr 28 '26	Sale	14.79	753	11,137	275,857	Apr 30 04:22 PM
Bergstrom Donald A	President, R&D	Apr 28 '26	Sale	14.79	1,490	22,037	418,557	Apr 30 04:20 PM
Catinazzo Thomas	Chief Financial Officer	Apr 09 '26	Option Exercise	5.22	1,800	9,396	215,667	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Apr 07 '26	Sale	13.01	17,717	230,498	213,867	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Apr 09 '26	Sale	15.00	1,800	27,000	213,867	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Mar 09 '26	Sale	10.06	17,717	178,233	231,584	Mar 11 04:30 PM
THOMAS CATINAZZO	Officer	Mar 09 '26	Proposed Sale	9.89	53,151	525,663		Mar 09 04:35 PM
Bergstrom Donald A	President, R&D	Jan 27 '26	Sale	7.62	18,895	143,980	422,733	Jan 29 04:22 PM
Bergstrom Donald A	President, R&D	Jan 28 '26	Sale	8.45	2,686	22,697	420,047	Jan 29 04:22 PM
Rahmer Peter	See remarks	Jan 27 '26	Sale	7.62	11,684	89,032	277,964	Jan 29 04:22 PM
Rahmer Peter	See remarks	Jan 28 '26	Sale	8.45	1,354	11,441	276,610	Jan 29 04:22 PM
Catinazzo Thomas	Chief Financial Officer	Jan 27 '26	Sale	7.62	13,820	105,308	250,996	Jan 29 04:20 PM
Catinazzo Thomas	Chief Financial Officer	Jan 28 '26	Sale	8.45	1,695	14,323	249,301	Jan 29 04:20 PM
Patel Sanjiv	President and CEO	Jan 06 '26	Sale	7.82	43,168	337,574	661,041	Jan 07 04:15 PM

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

M.B.A.Dr. Sanjiv K. Patel M.A.

Founder & Independent DirectorDr. Mark Murcko Ph.D.

Chief Financial OfficerMr. Thomas Catinazzo

Chief Corporate Development OfficerMr. Peter Rahmer

Ph.D.Dr. Donald A. Bergstrom M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLAY

Relay Therapeutics Inc

Upgrade your Finviz experience